



Microbiome-Based Therapies: Alternatives to, Complementing or Enhancing Antibiotic Treatments

Guest Editors:

Dr. Vitor Cabral

Instituto Gulbenkian de Ciência,
Oeiras, Portugal

Dr. Rita A. Oliveira

Duchossois Family Institute, The
University of Chicago, Chicago,
IL, USA

Deadline for manuscript
submissions:

15 June 2024

Message from the Guest Editors

Antibiotic therapies have been critical in saving lives. However, decades of antibiotics misuse posed a worldwide health burden with the rise of multidrug resistance and collateral damages to the commensal microbial communities that promote host health. This threatens to be the most challenging issues of our generation. Antibiotic treatment still is the most efficient therapy against bacterial infections and inflammatory diseases. Alternatives to antibiotics have been greatly needed although scarce, but also complementing therapies that can be used with antibiotics. These strategies will improve or replace antibiotic treatments, while attenuating their collateral effects on commensal bacteria, hence safeguarding the beneficial and protective effects of the natural microbial communities.

The aim of this Special Issue is to bridge the gap between these findings and promote a better understanding of the approaches being studied and their successes, fomenting a faster and more sustained advancement of the field to target antibiotic-induced microbiome dysbiosis and rise of antimicrobial resistance in important areas such as human health, agriculture, veterinary medicine, among others.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi